- Home
- NKTX vs ACRS Comparison
NKTX vs ACRS Comparison
Compare NKTX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- ACRS
- Stock Information
- Founded
- NKTX 2015
- ACRS 2012
- Country
- NKTX United States
- ACRS United States
- Employees
- NKTX N/A
- ACRS N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- ACRS Health Care
- Exchange
- NKTX Nasdaq
- ACRS Nasdaq
- Market Cap
- NKTX 170.8M
- ACRS 170.9M
- IPO Year
- NKTX 2020
- ACRS 2015
- Fundamental
- Price
- NKTX $2.00
- ACRS $1.59
- Analyst Decision
- NKTX Strong Buy
- ACRS Strong Buy
- Analyst Count
- NKTX 6
- ACRS 7
- Target Price
- NKTX $15.00
- ACRS $11.67
- AVG Volume (30 Days)
- NKTX 2.4M
- ACRS 1.2M
- Earning Date
- NKTX 03-26-2025
- ACRS 05-06-2025
- Dividend Yield
- NKTX N/A
- ACRS N/A
- EPS Growth
- NKTX N/A
- ACRS N/A
- EPS
- NKTX N/A
- ACRS N/A
- Revenue
- NKTX N/A
- ACRS $18,720,000.00
- Revenue This Year
- NKTX N/A
- ACRS N/A
- Revenue Next Year
- NKTX N/A
- ACRS N/A
- P/E Ratio
- NKTX N/A
- ACRS N/A
- Revenue Growth
- NKTX N/A
- ACRS N/A
- 52 Week Low
- NKTX $1.31
- ACRS $0.95
- 52 Week High
- NKTX $11.84
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NKTX 59.36
- ACRS 32.16
- Support Level
- NKTX $1.31
- ACRS $1.57
- Resistance Level
- NKTX $2.34
- ACRS $1.78
- Average True Range (ATR)
- NKTX 0.15
- ACRS 0.10
- MACD
- NKTX 0.05
- ACRS 0.03
- Stochastic Oscillator
- NKTX 66.99
- ACRS 33.93
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.